Eagle Pharmaceuticals, Inc. · OTC:EGRX

Eagle Pharmaceuticals — Investor Presentation (September 2023)

21 slides from Eagle Pharmaceuticals's investor presentation, Sep 27, 2023

  1. Slide 1: Company Overview September 2023

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 1 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. Company Overview September 2023

  2. Slide 2: Forward-Looking Statements

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 2 Forward - Looking Statements This presentation contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 19 95, as amended, and other securities law All statements other than statements of h

  3. Slide 3: Profit and gross margin continue to exceed internal projections

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 3 3 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. Eagle’s profit and gross margin continue to exceed internal projections. We expect further growth as our portfolio of products and underlying business continue to strengthen.

  4. Slide 4: A Diversified Pharmaceutical Company with Significant Opportunities for Growth

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 4 Eagle Pharmaceuticals: A Diversified Pharmaceutical Company with Significant Opportunities for Growth Substantial potential for further expansion Maintaining market share for bendamustine franchise Share of the commercial U.S. pemetrexed mark

  5. Slide 5: Strong Financial Position

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 5 Eagle Pharmaceuticals: Strong Financial Position Q2 2023 revenue of $64.6M and adjusted non - GAAP EBITDA of $20.7M † Gross margin of 74% and adjusted non - GAAP gross margin of 83% * † Oncology gross margin of 80% and adjusted non - GAAP gro

  6. Slide 6: EA-114 Product Candidate Provides Growth Opportunity; NDA Planned 2024

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 6 EA - 114 Product Candidate Provides Exciting Growth Opportunity; Eagle Plans to File NDA in 2024 1. IQVIA SMART – US Edition Monthly. ● Estrogen receptor antagonist used in the treatment of metastatic breast cancer in post - menopausal women

  7. Slide 7: Earnings Timeline – Actuals and Guidance

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 7 7 Earnings Timeline – Actuals and Guidance 2020 2021 2022 Previous 2023E Range Revised 2023E Range 2 Adjusted EBITDA (US$M) 1 $64.7 $28.2 $132.1 $74.0 - $80.0 $78.0 - $84.0 Diluted Adjusted Non - GAAP EPS 1 $3.54 $1.68 $7.79 $4.20 - $4.53 $4.

  8. Slide 8: Oncology & Acute Care Contribution

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 8 Oncology & Acute Care Contribution (US$M) 1. Adjusted non - GAAP EBITDA, adjusted non - GAAP Gross Profit, adjusted non - GAAP R&D expense and adjusted non - GAAP SG&A expense are non - GAAP financial measures. For descriptions and reconcilia

  9. Slide 9: Growth Continues with More Diversified Revenue Streams

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 9 9 Eagle Growth Continues with More Diversified Revenue Streams 2023 Expectations 21% 16% 15% 8% 19% 20% 57% 55% 79% 84% 85% 92% 81% 80% 43% 45% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2016 2017 2018 2019 2020 2021 2022 1H2023 Other Revenu

  10. Slide 10: Barhemsys and Byfavo Momentum Continues

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 10 Growth primarily driven by Eagle’s experienced commercial team and access in the hospital space An estimated 19,000 patients 1 were dosed with Barhemsys or Byfavo during the second quarter of 2023 275 health care facilities purchased the pro

  11. Slide 11: Business Development Strategy and Select Capital Spend

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 11 Eagle’s Business Development Strategy and Select Capital Spend Value OpEx Size Portfolio x Pursuing accretive acquisition opportunities x Leverage infrastructure x Opportunity for synergies / expense reductions x Potentially a ble to finance

  12. Slide 12: Eagle Product Portfolio

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 12 Eagle Product Portfolio Is Supported by 80 - Person Commercial Team RYANODEX ® For treatment of malignant hyperthermia BARHEMSYS ® For prevention of PONV*, and treatment of PONV in patients who received antiemetic prophylaxis with an agent o

  13. Slide 13: CAL02 Potential to Elevate the SOC for SCABP

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 13 CAL02 Has the Potential to Elevate the SOC for SCABP W ithout Contributing to Antibiotic Resistance ● CAL02 1 is a novel first - in - class broad - spectrum anti - virulence agent being developed for the treatment of severe community - acqui

  14. Slide 14: ENA-001: NCE for Acute Respiratory Depression

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 14 ENA - 001: An NCE with a Unique Mechanism of Action for Acute Respiratory Depression ● ENA - 001 1 is an investigational new chemical entity being developed by Enalare as an agnostic respiratory stimulant for multiple patient populations exp

  15. Slide 15: Financial Appendix

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 15 15 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. Financial Appendix

  16. Slide 16: Non-GAAP Financial Measures

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 16 Non - GAAP Financial Measures In addition to financial information prepared in accordance with U.S. GAAP, this presentation also contains non - GAAP financial m easures, including adjusted non - GAAP net income, adjusted non - GAAP EBITDA, a

  17. Slide 17: Net Income to Adjusted Non-GAAP EBITDA Reconciliation

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 17 17 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. Three Months Six Months Ended Ended 2022 2021 2020 Net income (loss) - GAAP 5,164$ 10,914$ 35,642$ (8,627)$ 11,989$ Add back: Interest expense, net of interest income 1,253 2,557 3,7

  18. Slide 18: Net Income to Adjusted Non-GAAP Net Income Reconciliation

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 18 18 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. Three Months Six Months Ended Ended 2022 2021 2020 Net income (loss) - GAAP 5,164$ 10,914$ 35,642$ (8,627)$ 11,989$ Adjustments: Cost of product revenues: Amortization expense 5,459

  19. Slide 19: Oncology Gross Profit Reconciliation

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 19 19 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. Three Months Six Months Ended Ended Revenue: PEMFEXY TM 19,400$ 42,348$ BELRAPZO® 6,848 13,198 BENDEKA® 3,780 6,174 TREAKISYM 728 2,083 Oncology product sales, net 30,756$ 63,803$ BE

  20. Slide 20: R&D and SG&A Non-GAAP Reconciliation

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 20 20 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 2023 2022 2023 2022 Research and development - GAAP 9,833$ 11,437$ 19,105$ 17,545$ Add back: Stock-based compensation expense 527 601 1,214 1,244 Depreciation expense 32 44 62 92 Sev

  21. Slide 21: Thank You!

    © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. 21 © 2023 Eagle Pharmaceuticals, Inc. All rights reserved. Thank You!

Eagle Pharmaceuticals — Investor Presentation (September 2023) on 6ix